Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’

Data monitoring committee has not yet conducted any interim efficacy analysis of the shot

- PMLiVE

Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

Earnings were particularly impacted by lower demand for top diabetes drug Trulicity

- PMLiVE

Warren Buffett’s greatest health lesson

He told us about it almost two decades ago – we didn’t pay attention

- PMLiVE

COVID-19 vaccine developers won’t face pre-approval FDA inspections for EUAs

Companies typically face inspections before gaining approval from the FDA

- PMLiVE

Novartis weathers the COVID-19 storm in Q3, lifts outlook

Core operating income increased by 11%, profits from net income drop

- PMLiVE

Researchers say COVID-19 antibody levels have fallen rapidly in the UK

Number of people testing positive for antibodies fell by 26.5% between June and September

- PMLiVE

Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue

Bamlanivimab is being studied in a number of additional ongoing trials

- PMLiVE

Exploring the potential of eosinophils

GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils

Eliminating pharmaceutical rebates, is this déjà vu?

By Andrew Parece and Matthew Majewski

AstraZeneca AZ

AZ’s COVID-19 vaccine shows promise in younger and older adults

Company said vaccine produces similar immune response in younger and older adults

- PMLiVE

Both AZ and J&J set to resume US COVID-19 vaccine trials

Both companies paused their trials after separate participant illness events

Bayer symbol

Bayer pays an initial $2bn for gene therapy firm AskBio

Acquisition will expand Bayers’s pipeline with preclinical/clinical candidates

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links